Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon

Journal of Medical Virology

Volumn 84, Issue 5, 2012, Pages 721-727

  Ceccarelli, Laura ^a   Salpini, Romina ^b   Moudourou, Sylvie ^c   Cento, Valeria ^b   Santoro, Maria M ^b   Fokam, Joseph ^c   Takou, Desire ^c   Nanfack, Aubin ^c   Dori, Luca ^a   Torimiro, Judith ^c   Sarmati, Loredana ^a   Andreoni, Massimo ^a   Perno, Carlo F ^b   Colizzi, Vittorio ^c   Cappelli, Giulia ^c,d  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Laboratory of Systems Biology   (Cameroon)

^d CNR   (Italy)

Author keywords

HIV 1 diversity; Non B subtypes; Resource limited settings; Therapeutic failure; Transmitted drug resistance

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; TREATMENT FAILURE; VIRUS GENE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; CAMEROON; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84858609379     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23244     Document Type: Article

References (36)

1. Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, Mokondji E, Nambei WS, Peyou-Ndi MM, Moka JJ, Delaporte E, Peeters M. 2009. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 14: 401- 411.
2. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
3. Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET, Haldar B, Powell RL, Jarido V, Hewlett IK, Nyambi PN. 2010. HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naive to HAART in Cameroon. J Med Virol 82: 187- 196.
4. Camacho R. 2006. In: The significance of subtype-related genetic variability: Controversies and unanswered questions, Geretti AM, editors. Antiretroviral resistance in clinical practice. London: Mediscript, Chapter 13.
5. Carr JK, Wolfe ND, Torimiro JN, Tamoufe U, Mpoudi-Ngole E, Eyzaguirre L, Birx DL, McCutchan FE, Burke DS. 2010. HIV-1 Recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: Eolutionary relics? Retrovirology 7: 39.
6. Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d'Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF. 2007. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 81: 11507- 11519.
7. Chan PA, Kantor R. 2009. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther 3: 447- 465.
8. Derache A, Maiga AI, Traore O, Akonde A, Cisse M, Jarrousse B, Koita V, Diarra B, Carcelain G, Barin F, Pizzocolo C, Pizarro L, Katlama C, Calvez V, Marcelin AG. 2008. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 62: 456- 463.
9. Esbjörnsson J, Månsson F, Martínez-Arias W, Vincic E, Biague AJ, da Silva ZJ, Fenyö EM, Norrgren H, Medstrand P. 2010. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease indication of an evolving epidemic in West Africa. Retrovirology 22: 7- 23.
10. Garrido C, Soriano V, De Mendoza C. 2010. New therapeutic strategies for raltegravir. J Antimicrob Chemother 65: 218- 223.
11. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K. 2006. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368: 505- 510.
12. Guindon S, Gascuel O. 2003. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52: 696- 704.
13. Hughes A, Barber T, Nelson M. 2008. New treatment options for HIV salvage patients: An overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 57: 1- 10.
14. Huson DH, Bryant D. 2006. Application of phylogenetic networks in evolutionry studies. Mol Biol Evol 23: 254- 267.
15. Jacobs GB, Laten A, van Rensburg EJ, Bodem J, Weissbrich B, Rethwilm A, Preiser W, Engelbrecht S. 2008. Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retrov 24: 1009- 1012.
16. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, Nguyen DP, Katzenstein D, Fessel WJ. 2004. Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy. AIDS 18: 1503- 1511.
17. Kosakovsky Pond SL, Posada D, Stawiski E, Chappey C, Poon AF, Hughes G, Fearnhill E, Gravenor MB, Leigh Brown MB, Frost AJ. 2009. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol 5: e1000581.
18. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E. 2009. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 48: 1318- 1322.
19. Kuate S, Mikolajczyk RT, Forgwei GW, Tih PM, Welty TK, Kretzschmar M. 2009. Time trends and regional differences in the prevalence of HIV Infection among women attending antenatal clinics in two provinces in Cameroon. J Acquir Immune Defic Syndr 52: 258- 264.
20. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC. 1999. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73: 152- 160.
21. Los Alamos National Laboratory HIV Sequence Database
22. National AIDS Control Commettee. The impact of HIV and AIDS in Cameroon through 2020. September 2010.
23. Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, Salata R, Arts EJ. 2008. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug-resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 46: 177- 184.
24. Nyombi BM, Kristiansen KI, Bjune G, Muller F, Holm-Hansen C. 2008. Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania. AIDS Res Hum Retrov 24: 761- 769.
25. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. 2002. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29: 184- 190.
26. Peeters M, Toure-Kane C, Nkengasong JN. 2003. Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. AIDS 17: 2547- 2560.
27. Posada D, Buckley TR. 2004. Model selection and model averaging in phylogenetics: Advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol 53: 793- 808.
28. Simon F, Mauclère P, Roques P, Loussert-Ajaka I, Müller-Trutwin MC, Saragosti S, Georges-Courbot MC, Barré-Sinoussi F, Brun-Vézinet F. 1998. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 4: 1001- 1002.
29. Struck D, Perez BD, Devaux C, Schmit JC. 2010. COMET: A Novel approach to HIV-1 subtype prediction [Abstract]. Presented at 8th European HIV Drug Resistance Workshop 2010. Abstract 88.
30. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, Mbanya D, Kaptué L, Ndembi N, Gürtler L, Devare S, Brennan CA. 2011. Confirmation of putative HIV-1 group P in Cameroon. J Virol 85: 1403- 1407.
31. Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, Noumssi N, Tardy M, Sawadogo A, Drabo J, Hien H, Zekeng L, Delaporte E, Peeters M. 2006. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 11: 575- 579.
32. Vessière A, Nerrienet E, Kfuţwah A, Menu E, Tejiokem M, Pinson-Recordon P, Barré-Sinoussi F, Fleury H, Ayouba A. 2006. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaoundé, Cameroon. J Acquir Immune Defic Syndr 42: 256- 258.
33. World Health Organization (WHO). 2009a. Joint United Nations Program on HIV/AIDS, United Nations Children's Fund. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector: Progress report. Geneva, Switzerland: WHO.
34. World Health Organization (WHO). 2009b. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Geneva, Switzerland: WHO.
35. WHO and UNAIDS. 2006. Progress on global access to HIV antiretroviral therapy: A report on "3 by 5" and beyond. Geneva: WHO.
36. Wilgenbusch JC, Swofford D. 2003. Inferring evolutionary trees with PAUP*. Curr Protoc Bioinformatics.